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1. Introduction  
The process of drug delivery and disposition in the modern scientific aspect is very 
complex. Advances in many fields are converging to make the commercialisation of 
advanced drug delivery concepts possible. It integrates many disciplines, including 
biotechnology, medicine and pharmacology. Innovative devices should protect labile active 
ingredients, precisely control drug release kinetics and minimise the release of the drug to 
non-target sites. Rapid advances in these areas led to the revolutionary change in discovery 
of new methods of drug delivery and disposition.  
In the last two decades, interest in nanometre-size particles such dendrimers, liposomes, 
micelles and polymeric particles has increased significantly. As a new drug delivery system, 
nanoparticles resolved many drug pharmacokinetics problems related with precisely control 
drug release, poor stability and toxicity of active ingredient. Crucially, the nano-sized 
particles have very important advantage in intravenous application (Ilium et al., 1982). 
Generally, their circulation time is limited by the smallest blood capillaries in human 
vascular system (Table 1) (Arruebo et al., 2007; Yoo et al., 2011). Therefore, the particles size 
smaller than 1000 nm are usually objects of interest as a new potential carriers for efficient 
drug delivery (Figure 1). Also, the other parameters including shape and surface activity 
influence on their distribution and elimination from vascular system.  
In the last years, a new drug targeting employing magnetic particles as a drug carriers is a 
promising tool for the more effective and safe chemotherapy. Initially, the micro- and nano-
sized magnetic particles (MMPs; MNPs) provided an original modern technology for 
bioseparations, especially for ligand “fishing”, protein, enzyme, DNA, RNA and cell 
isolation or purification (Corchero & Villaverde, 2009). Because of the superparamagnetic 
properties, magnetic particles can be used to simply isolate any target and can be linked 
with diverse manual and automated applications (Marszałł et al., 2008, 2011a).  
The stability of captured protein/enzyme/drug depends on the morphology of the 
magnetic microspheres. There are many materials available with magnetic properties. 
However, the iron oxide (Fe3O4) or meghemite (γ-Fe2O3) are most commonly employed for 
in vivo applications. The materials, such as cobalt, chromium, nickel and other iron-based 
metal oxides, such as CoFe2O4, NiFe2O4, MnFe2O4 should be limited for biomedical 
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applications due to their high toxicity and long-term changes in enzyme kinetics. The ferrite 
nanoparticles have large surface area to volume ratio and can adsorb plasma proteins and 
other biomolecules as well as agglomerate in vivo (Douziech-Eyrolles et al., 2007). 
Additionally, the magnetic nanoparticles without coating are rapidly cleared by 
macrophages in the reticulo-endothelial system. Because of the high physicochemical 
activity of the surface of magnetic particles and risk of corrosion process they are often 
encapsulated or coated with protective material: carbohydrates, lipids, gold, proteins and 
synthetic polymers.  
 
Classes of blood capillaries Permeability 
(size) 
Location 
Tight-junction capillaries < 1nm Blood-brain barrier (BBB) 
Continuous capillaries ~ 6 nm Muscle, lung, skin 
Fenestrated capillaries ~ 5-60 nm Kidney, intestine and some 
endocrine and exocrine glands 
Sinusoid capillaries  ~ 100-1000 nm Liver, spleen, bone narrow 
Table 1. Different classes of blood capillaries in human vascular system  
(Arruebo et al., 2007). 
 -drug 
       
 Dendrimers   Micelle   Liposomes 
 3-5 nm    5-10 nm   100-150 nm 
 drug encapsulated 
 or attached 
Fig. 1. The most popular nano-sized drug delivery systems for in vitro and in vivo 
applications.  
With the development of improved syntheses and techniques for determining the particle-
size distribution the new name of MNPs was defined as a superparamagnetic iron oxide 
naoparticles (SPIONs). The main principles of SPIONs compared to ferromagnetic particles 
is lack of permanent magnetic dipole. The promising perspectives for biomedical 
application of SPIONs is that the moment of each particles fluctuates between different 
directions at the rate given by the temperature and the applied magnetic field (Woodward et 
al., 2007). This phenomenon allows for the accumulation of local chemotherapeutic agent in 
vivo with the use of external magnetic field which can be controlled by magnetisation 
expressed as: 
1M c L( ) c [coth( ) ( / )]         
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where c is particle concentration, μ is the magnetic moment of the particle and L( ) is the 
Langevin function in which  =μH/kT, where H is the applied magnetic field, k is the 
Boltzman constant and T is the temperature in Kelvin. μ is the magnetic moment of the 
particle which is related to the particle volume (v) by μ = vMs where Ms is the saturation 
magnetization.  
SPIONs have interesting properties such as high field irreversibility, high saturation field 
and they do not show magnetic interaction after the external magnetic field is removed 
(Mahmoudi et al., 2011). The advantage of SPIONs compared to ferromagnetic particles is 
that the standard particles tend to agglomerate due to their permanent magnetic dipoles. 
Thus, the suspension of SPIONs produce very stable ferrofluids which in vivo application 
are still investigated. 
The use of solid polymer matrix or core-shell type silica-based superpara- and paramagnetic 
particles as a carriers for binding proteins, enzymes and drugs received increasing attention 
in drug delivery studies. The external multifunctional layer of magnetic beads provides 
reactive groups that are able to covalently conjugate aldehyde, amine, carboxy, hydroxyl, 
ketone, sulfhydryl and organic linkers for formation of stable linkage (Figure 2). 
  
Fig. 2. The core-shell type silica-based superparamagnetic iron oxide nanoparticle (SPION) 
with different functional groups on the surface. 
The pioneering “medical” application in the treatment of lymphatic nodes and metastases 
based on injecting “metallic particles” preheated in a magnetic field was first published in 1957 
(Gilchrist et al., 1957). However, the potential medical application of new finding was limited 
by the poor performance of particles. In recent years, the new nanotechnologies allowed for 
the precise manufacturing of nanoparticles with specific size, surface area and biocompatibility 
with the view of in vivo application. Moreover, the magnetic nanoparticles offer many exciting 
possibilities for development not only a new potential drug carriers but also are being 
investigated as a magnetic contrast agents in magnetic resonance imaging (MRI) and 
hyperthermia agents in hyperthermia cancer treatment.  
SPION 
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2. Magnetic drug delivery system in cancer therapy 
2.1 Ionic binding of the drug to the magnetic nanoparticles 
In 1978, magnetic particles were first applied as a new class of drug target (Widder et al., 
1978). The superparamagnetic properties of the magnetic micro- and nanoparticles have 
opened promising new perspectives for in vivo application. The magnetic nanoparticles as 
drug carriers provide huge opportunities in cancer treatment. The use of such carriers in 
targeted therapy considerably reduces the side effects of conventional chemotherapy. A 
novel carrier system allows for intravenous drug delivery and the local accumulation of 
chemotherapeutic agent which is comparable to that achieved by the administration of a 
100-fold higher dose of the drug. The magnetic drug targeting enables the fast and precise 
location of drug in the body with the use of external magnetic field. After the vascular 
injection, the particles can be transported and concentrated at desired location with the help 
of magnet (Figure 3). For drug delivery application the optimal size of nanoparticles should 
be in the range from 10 to 200 nm. The micrometer size below 200 allows for systematic 
administration in circulation system and also into targeted tissue as well as enhance the 
ability of nanoparticles to evade the biological particulate filters, such as the reticulo-
endothelial system (Tran & Webster, 2010). To date, magnetic drug targeting has been 
studied mostly in pre-clinical models for cancer therapy with intravascular administration 
of chemotherapeutics. 
The Phase I clinical trial demonstrated that the epirubicin attached to magnetic fluids 
(ferrofluids) could be concentrated in locally advanced tumor by magnetic field. The drug 
was bound to phosphate groups of starch polymers which covered the iron oxide core with 
particle size of 100 nm. The “magnetic epirubicin” with doses in the range of 5-100mg/m2 
was infused i.v. over 15 min into a vein located contra laterally to the tumor in patients with 
advanced and unsuccessfully pretreated metastatic breast cancer, chondrosarcoma and 
squamous cell carcinoma. The neodymium magnets were large 8x4x2cm or 3x3x1cm and 
were kept at a distance of 0.5 cm to tumor surface. The clinical trials provided the important 
information about the conditions of drug release, distribution and mechanism of action. The 
researchers concluded that the size of magnetic particles should be close to 1μm to increase 
of their accumulation in tumor site and, consequently, the concentration of the drug (Lübbe 
et al., 1996). The better optimization of ionic binding epirubicin on to the surface of magnetic 
nanoparticles also can improve the drug release in physiological parameters. Hence, a new 
group of novel nano- and micro magnetic particles consisting of various synthetic and 
natural matrices were investigated (Bergemann et al., 1999). 
The idea for ionic binding of the drug to magnetic particles was continued because of the 
ligand/drug can be easily released from the matrix by simply changing either ionic strength 
or the pH. The surface of polyvinylalcohol, polyacrylates and polyacharide matrices 
consisted of cationic exchange groups (i.e. sulphate, phosphate) is able to ionically bind 
pharmaceutical active compound or biological substances. Furthermore, the modified starch 
nanoprticles with diethylaminoethyl (DEAE) groups can bind to negatively charged cell 
membrane. This tool was successful used for separation cells and gene transfer by magnetic 
transfection of cytokine-induced killer cells (CIK-cells) with plasmid DNA. The 
representative cationic and anionic nanopartcles are presented in Figure 4 (Bergemann et al., 
1999).  
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Fig. 3. The scheme of in vivo application of magnetic drug delivery system after the vascular 
injection; superparamagnetic iron oxide nanoparticles (SPIONs), external magnet (M). 
a)     b) 
  
c)     d) 
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Fig. 4. The representative ion-exchange-active magnetic nanoparticles: cationic (a), anionic 
(b) as well as loaded with cytostatic drugs: epirubicin (c) and mitoxantrone (d). 
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The magnetic dug targeting approach offers a new opportunity to treat malignant tumors 
locoregionally. The treatment of squamous cell carcinoma in rabbits with nanoparticles 
covered with modified starch to which the mitoxantrone was ionically bound, caused 
complete and permanent remission of the cancer compared with control group (Alexiou et 
al., 2000). The advantage of ionically bound mitoxantrone is that the anticancer agent is able 
to desorb from the magnetic caries after the 30 min (half-time). Determination of time of 
desorption is very important because the ferrofluids have to be transferred to the tumor 
region by the magnetic field. Next, the drug must dissociate to act within the tumor. 
Generally, the total release of drug from the magnetic carriers is recommended at less than  
1 h. The 100 nm particles size and strong magnetic field (1.7 Tesla) are optimal for efficient 
treatment of smaller animals such as mouse or rat. However, the appropriate magnetic field 
strength and particle size for treatment of deep body cavities and human cancer has to be 
optimised. The extensive biodistribution study with Iod123 – labeled ferrofluids 
demonstrated that magnetic flux density is an important factor in magnetic drug targeting 
(Alexiou et al., 2005).  
2.2 Covalent binding of the drug to the magnetic nanoparticles 
On the contrary to ionic binding, the covalent binding of the drug to magnetic particles 
prevents unwanted drug release in a physiological environment. Hence, the new strategy is 
based on the covalent coupling of antibodies, nucleic acids, proteins and active compounds 
on to the surface of functional magnetic particles coated with polymer or silica. The most 
popular surface groups such as amine, carboxy and aldehyde allow for a covalent conjugate 
almost any custom ligand (drug) (Figure 5). The coupling efficiency depends on the 
functional group density and type of linker. The magnetic particles with primary amine or 
aldehyde functional groups on the surface are used to covalently conjugate primary amine - 
containing ligands. The particles coated with carboxyl functional groups on the surface can 
be covalently attached to primary amine- containing ligands via a stable amide bond.  
This strategy was proposed for methotrexate-modified superparamagnetic nanoparticles as 
a drug carrier in controlled drug delivery, targeted at cancer diagnostics and therapeutics 
(Kohler et al., 2005). The nanoparticles were modified with (3-aminopropyl)-
trimethoxysilane (APS) to form aminopropyl layer and subsequently conjugated with 
methotrexate through amidation using the 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC) as a crosslinking agent. 
The in vitro studies in both human breast cancer (MCF-7) and human cervical cancer (HeLa) 
cells demonstrated the successful internalization of used methotrexate conjugates into 
lysosomes as a promising tool for anticancer activity. Methotrexate is an analogue of folic 
acid. Folic acid is generally recognized as an effective targeting agent which receptors are 
overexpressed on the cell membranes of many cancer cells. Hence, the methotrexate is used 
as a therapeutic agent for the treatment of several forms of cancer (carcinomas, lymphomas, 
breast, head, leukemia, neck cancer) (Messmann & Allegra, 2001). The proposed 
methotrexate-modified superparamagnetic nanoparticles enable real-time monitoring of 
drug carriers by MRI after intravenous drug delivery. Moreover, the methotrexate is not 
released from magnetic carriers due to the high stability binding of drug-particles in 
physiological parameters. Curiously, the covalent-amide bond is broken under conditions  
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a)   
b)  
c)  
d)  
 
Fig. 5. The covalent immobilization of drugs on to the (a) aldehyde-, (b) amine- or (c) 
carboxy-terminated magnetic nanoparticles surface and metotrexate on to the surface 
modified with (3-aminopropyl)-trimethoxysilane (APS) (d). 
present in the lysosomal compartment. The intracellular uptake of the metohrexate-magnetic 
nanoparticle conjugates is assumed to depend on a receptor-mediated endocytosis (Figure 6) 
(Kohler et al., 2005). Next, they are transported as a endosomes and fused with lyposomes 
containing proteases and low pH. In this condition, the peptide bond between the methotrexate 
and magnetic carriers is broken and anticancer drug is released inside the target cell.  
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Fig. 6. The intracellular model of the uptake of methotrexate (MTX) – modified 
nanoparticles into breast cancer cells (Kohler et al., 2005).  
(Adapted with permission from @ 2005 American Chemical Society). 
2.3 Magnetic nanoparticles for tumor imaging and therapy 
Magnetic resonance imaging (MRI) is widely used as a screening non-invasive method of the 
human body. It is also used to monitor cell migration to targets tissue in cell-based therapy. 
The fact that the magnetic nanoparticles with labeled cells or as a drug targeting can be 
visualized using MRI, they are a new alternatives and noninvasive imaging techniques for 
monitoring of cell or drug migration to target tissue. For in vitro application, their advanced 
development in cell manipulation/therapy, biomolecule separation, selection and purification 
was found (Gijs, 2004). The ability to produce a distortion in magnetic field monitored by MRI, 
allowed for the increasing application of magnetic beads in vivo. The different strategies of the 
use of anionic magnetic nanoparticles (AMNPs), ultrasmall paramagnetic iron oxides 
(USPIOs) and superparamagnetic iron oxide nanoparticles (SPIONs) have been demonstrated 
as a contrast agents to identify magnetically labelled cells during MRI monitoring of cellular 
therapies (Wilhelm & Gazeau, 2008; Modo et al., 2005). The demonstrated studies confirm the 
efficacy of labelling with magnetic particles for a wide variety of mammalian cells, including 
non- and phagocytic cells, different species, cell size, types and culture properties. The MRI 
contrast is a result of different signal intensities of tissue, produced in response to applied 
radio frequency pulses (Gijs, 2004). Labelled-specific magnetic particles provide a suitable 
source of contrast and convenient tool for the non-invasive study of biological processes, such 
a tumor imaging and therapy with the use of MRI.  
The use of magnetic particles can significantly improve hyperthermia cancer treatment 
(Marszałł, 2011b). This therapy involves raising the temperature of the target tissue to  
43-46˚C. In this conditions its sensitivity to chemo- and radiotherapy increases and may 
additionally stimulate activities of the host immune system (Ang et al., 2007). The problem 
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with hypethermia therapy is the heating the large area of tissue or body in general, not only 
the tumor region. The healthy tissues adsorb microwave, laser and ultrasound energy which 
can cause burns and blisters (Phillips & Johnson, 2005). Magnetic hyperthermia is one of the 
anti-cancer approches based on the introduction of ferro- or superparamagnetic particles 
into the tumor tissue. The main advantage of magnetic particle hyperthermia is that the 
particles can heat previously localized target issue by external magnetic field. Next, under 
an applied magnetic field, energy is converted to thermal energy in tumor region which 
destroys cancer tissues (Figure 7) (Cole et al., 2011).  
 
Fig. 7. Scheme of magnetic hyperthermia treatment of affected tissue; (a) accumulation of 
magnetic nanoparticles (MNPs) by the magnet at the tumor site; (b) exposition of tumor cells 
to an altering current (AC) magnetic field (Cole et al., 2011). (Adapted with permission from 
@ 2011 Elsevier). 
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Cancer-specific binding agents such as antibodies, hormones and other exo- and 
endogenous substances attached to magnetic nanoparticles has promising implications for 
magnetic fluid hyperthermia treatment (MFH) of breast, prostate and thyroid cancer or in 
vivo magnetic resonance imaging of acute brain inflammation (Phillips & Johnson, 2005; 
McAteer et al., 2007). MFH cancer treatment is based on the injecting a fluid containing 
magnetic nanoparticles directly into cancer region and the use of altering magnetic filed to 
generate the heat and destroy the tumor. Alternatively, the fluid can be injected into an 
artery that supplies the tumor with blood. However the location of the magnetic fluid 
should be precisely to minimize the effect of MFH. Attaching other cancer specific agents 
onto the surface of magnetic particles such as monoclonal antibodies or viruses has also 
promising applications. The agents can be modified to selectively bind cancerous cells. For 
instance, the genetic material in the viruses can be replaced with anticancer drug and than 
can be precisely released in cancer area at elevated temperature. The promising benefits of 
hyperthermia cancer treatment open a new perspectives for application of magnetic 
particles in cancer treatment.  
3. Nanomagnetosols 
Aerosol drug delivery system allows for the pulmonary drug administration delivery of 
therapeutic agents. The non-invasive drug delivery is mainly used for treatment of lung 
disorders such as asthma, chronic obstructive pulmonary disease and lung cancer. 
Pulmonary delivered drugs are rapidly absorbed alike to other mucosal surfaces. The 
appropriate size of aerosols droplets determines the passive targeting by their deposition in 
different lung regions. However the exact targeting to specific lung regions other than 
airways or the lung periphery has not been achieved to date (Dames et al., 2007). The high 
and effective drug concentration at disease site in standard chemotherapy in lung cancer 
with cytotoxic drugs is particularly difficult. The problem is that the cytotoxic potency of 
chemoterapeutics is not limited to cancer region.  
The innovative study reports for the first time target aerosol delivery to the lung achieved 
with aerosol droplets comprising superparamagnetic iron oxide nanoparticles in 
combination with a target-directed magnetic gradient field. The high efficiency of aerosol 
droplets comprising SPIONs in combination with external magnetic gradient field was 
confirmed by computer aided simulation and demonstrated experimentally in mice. In 
contrast to intravenous magnetic drug targeting, the pulmonary drug administration has 
less limitations of the drug binding capacity of the nanoparticles. The new drug carriers, 
also called as a nanomagnetosols, offer high a flexibility of the system (Dames et al., 2007). 
The main advantage is that drug dose can be easily adjusted by the changing the drug 
concentration in the magnetic particles solution. Additionally, different drugs can be 
attached in different manner to the magnetic particles and also they can be co-delivered 
with other nanocarriers such as liposomes.  
The successful magnetic aerosol targeting in vivo with plasmid DNA (pDNA) was achieved 
in intact mouse. The electromagnet with the iron circuit and the tip comprising an iron-
cobalt alloy allows for accurate positioning of the SPIONs in selected site of the lung. The 
amount of deposited pDNA did not differ between the left and right lung in the absence of 
the external magnetic field. A twofold higher amount of pDNA was evaluated in the 
magnetized right lung than in unmagnetized left lung (Dames et al., 2007). Moreover, the 
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authors conclude that the nanomagnetosol droplets with SPIONs are responsible for their 
transport, deposition the accumulation of the attached ligand/drug in affected tissue and 
not the single SPION as was supposed previously.  
The anatomy of human lung also allows for the implementation of magnetosols in targeted 
therapy. The concept of non-invasive targeted delivery of magnetic aerosol droplets to the 
lung is presented in Figure 8. In last decade, the use of new drug delivery approach in the 
small animal were often demonstrated and well elaborated. The results confirm the higher 
deposition (~12%) of superparamagnetic nanoparticles (of ~50 nm diameter) on the 
magnetized airway surface and only ~4% on the unmagnetized airway area (Dames et al.,  
 
 
 
Fig. 8. The concept of non-invasive delivery of magnetic aerosol droplets to the human lungs 
and concentrated to the target site (tumor) with the help of magnet. 
External magnet  
Magnetic aerosol 
droplets with 
chemotherapeutic 
attached to SPION 
Affected lung 
tissue (tumor) 
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2007). Crucially, the non-deposited aerosol droplets can be transferred to further lung zones 
or exhaled. Regardless of the advantages for aerosol droplets with magnetic particles, the 
objective risk assessment studies have to be performed. Many of studies confirmed that the 
metal oxide particles are very toxic, especially in the pulmonary system (Machado et al., 
2010). Nowadays, the in vitro studies are focused on the characterization and cytotoxic 
assessment of aerosol particulates, especially the nanoparticles based on heavy alloys W-Fe-
Ni and W-Fe-Co. The exposure to Co, Ni, W and Fe can cause pulmonary fibrosis asthma, 
oedema and pneumonia among other effects. 
The cytotoxic assessment studies of aerosol particulates are usually performed with the use 
of model for lung tissue – human epithelial cells (A549). The use of different filter exposure 
cytotoxicity assays allow to assess the inflammatory and related respiaratory health effects. 
Generally, the inhaled ~1μm particulates are moved by cilia of the bronchial epithelial cells 
towards the upper respiratory tract. The nanoparticles at size of <100nm can accumulate, 
aggregate and even cause oxidative stress and inflammation. So far it is proved that the 
most important parameters that can affect cytotoxicity are chemical composition, size and 
time of deposition of magnetic nanoparticles. Because of a lack of detailed limitations 
regarding the in vivo use of nanomagnetosols, it is necessary to continue the risk assessment 
studies and establish the well-defined regulations.  
4. Magnetic drug delivery system in antimicrobial and antiviral therapy 
The magnetic nanoparticles are also promising carries for antibacterial agents such copper 
and silver and can provide an alternative treatment for bacterial infections. As known, silver 
is distinguished by extraordinary inhibitory and bactericidal properties for a broad 
spectrum of bacterial strains. Antibacterial coatings based on hydrogen bonded multilayer 
containing in situ synthesized silver magnetic nanoparticles can be delivered to a specific 
region to localize a high concentration of antibacterial silver while maintaining a low 
concentration in general (Lee et al., 2005). The silver multilayer assembled on spherical 
support such as magnetic micro- or nanospheres were localized and focused by external 
magnetic field and showed excellent antibacterial properties against the Gram-positive 
strain Staphylococcus epidermidis and the Gram-negative strain Escherichia coli. It is expected 
that the modification of silver particles multilayer by the increase of surface-volume ratios 
can improve the antibacterial treatment (Tran & Webster, 2010).  
The other studies demonstrates that the magnetic formulation of 3’-azido-3’-
deoxythymidine-5’-triphosphate (AZTTP) is a new potential drug carries for targeted 
delivery across the blood brain barrier (Saiyed et al., 2009, 2010). Nucleoside and nucleotide 
analog reverse transcriptase inhibitors (NRTIs) are important part of the antiretroviral 
therapy (ART). Their inefficient cellular phosphorylation cause a limitation for treatment of 
human immunodeficiency virus (HIV). Main assumption of the in vitro study is that active 
NRTIs can directly bind to magnetic nanoparticles by ionic interaction and can inhibit HIV-1 
replication. The development of magnetic AZTTP liposomal nanoformulation (150 nm) 
allows to cross blood brain barrier model by direct transport or via monocyte-mediated 
transport by external magnetic field. Hence, the magnetic carriers give a new opportunity to 
for treatment of neurological disorders. 
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5. Conclusion 
The micro- and nanoparticle technology is highly novel and offers many possibilities for 
future development of new drug delivery systems. The innovative methods for drug 
targeting and delivery based on the micro- and nano-sized magnetic support provide a 
numerous advantages compared to conventional drug delivery systems. Presently, only 
molecular targeting ligands coupled to magnetic particles are successfully used and 
commercial available as contrast agents in MRI. Although the magnetic particles possess 
unique and useful properties for biomedical and pharmaceutical applications, they also 
carry potential health risks. The small size and high surface area to volume ratio of magnetic 
nanoparticles may have important implications due to higher biological activity per given 
mass compared to larger particulate forms (Helland et al., 2008). That may cause their 
remarkable activity and toxicity effect. Therefore, the material used for surface coating of the 
magnetic particles for in vivo application must not only be nontoxic but also biocompatible. 
So far there are no criteria and tests for evaluation of toxicity level, parameters of release as 
well as uptake magnetically targeted drugs. Regarding the in vivo application, it will have 
to be proved, that the new drug carriers possess not only useful properties but also are quit 
safe for environment and human health. Hence, the Food and Drug Administration issued a 
report to consider developing guidance for regulation of nanotechnology products and their 
adaptation from science to biomedical application.  
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